Join
Live feed
·
PRReleasevia Quantisnow
Akero Therapeutics Inc. logo

Akero Therapeutics to Present Results from Phase 2b Expansion Cohort of SYMMETRY Trial Evaluating Efruxifermin in Combination with GLP-1

ByQuantisnow·Wall Street's wire, on your screen.
AKRO· Akero Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track AKRO (Akero Therapeutics Inc.) and more on Quantisnow.